
The Irish Pharmaceutical Healthcare Association (IPHA) has welcomed the new four-year framework agreement, expressing confidence that it will allow more innovative medicines to reach patients faster, and describing it as a positive step in supporting the life sciences industry in Ireland.
This deal on the pricing and supply of medicines reflects a continued desire on all sides to invest in treatments that improve outcomes for patients in Ireland and speed up the process of reimbursing new medicines in compliance with the law.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
| Headless Content Management with Blaze